Ferdous M. Barlaskar

971 total citations · 1 hit paper
10 papers, 697 citations indexed

About

Ferdous M. Barlaskar is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Ferdous M. Barlaskar has authored 10 papers receiving a total of 697 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 4 papers in Cancer Research and 3 papers in Surgery. Recurrent topics in Ferdous M. Barlaskar's work include Cancer, Hypoxia, and Metabolism (4 papers), Adrenal and Paraganglionic Tumors (3 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Ferdous M. Barlaskar is often cited by papers focused on Cancer, Hypoxia, and Metabolism (4 papers), Adrenal and Paraganglionic Tumors (3 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Ferdous M. Barlaskar collaborates with scholars based in United States, Australia and United Kingdom. Ferdous M. Barlaskar's co-authors include Gary D. Hammer, Alex C. Kim, Joanne H. Heaton, Thomas J. Giordano, Dafydd G. Thomas, Rork Kuick, Paul A. Walton, Laura J. Terlecky, Holly Edwards and Stanley R. Terlecky and has published in prestigious journals such as Journal of Clinical Oncology, Endocrine Reviews and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Ferdous M. Barlaskar

9 papers receiving 693 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

2023 124 citations Eric Van Cutsem, Maria Di Bartolomeo et al. The Lancet Oncology profile →

Peers

Ferdous M. Barlaskar

SURGE

CR

MB

EDM

ONCOL

Leandro M. Colli Brazil

Erica Dugnani Italy

Luis Gustavo Perez‐Rivas Germany

Oliver Umland United States

F. Mirshahi France

Lei Gong China

Iljana Gaffar United States

Jarkko Soronen Finland

R. Yoshiyuki Osamura Japan

Leandro M. Colli Brazil

Ferdous M. Barlaskar

144 ×0.5

SURGE

139 ×0.5

CR

264 ×1.0

MB

257 ×1.5

EDM

170 ×1.4

ONCOL

Citations per year, relative to Ferdous M. Barlaskar Ferdous M. Barlaskar (= 1×) peers Leandro M. Colli

Countries citing papers authored by Ferdous M. Barlaskar

Since Specialization

Citations

This map shows the geographic impact of Ferdous M. Barlaskar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ferdous M. Barlaskar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ferdous M. Barlaskar more than expected).

Fields of papers citing papers by Ferdous M. Barlaskar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ferdous M. Barlaskar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ferdous M. Barlaskar. The network helps show where Ferdous M. Barlaskar may publish in the future.

Co-authorship network of co-authors of Ferdous M. Barlaskar

This figure shows the co-authorship network connecting the top 25 collaborators of Ferdous M. Barlaskar. A scholar is included among the top collaborators of Ferdous M. Barlaskar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ferdous M. Barlaskar. Ferdous M. Barlaskar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Khattak, Adnan, Debashis Sarker, Theresa Medina, et al.. (2025). 1515MO Clinical outcomes and PD-L1 expression analyses from a trial of mRNA-4359 plus pembrolizumab in checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma. Annals of Oncology. 36. S844–S845.

2.

Jimeno, Antonio, Randy F. Sweis, Julie E. Bauman, et al.. (2024). 663P First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumors. Annals of Oncology. 35. S521–S522. 5 indexed citations

3.

Cutsem, Eric Van, Maria Di Bartolomeo, Elizabeth Smyth, et al.. (2023). Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. The Lancet Oncology. 24(7). 744–756. 124 indexed citations breakdown →

4.

Powderly, John D., Ryan J. Sullivan, Martin Gutierrez, et al.. (2023). Phase 1/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). TPS2676–TPS2676. 14 indexed citations

5.

Hunter, Bradley D., Megan M. Herr, Ferdous M. Barlaskar, et al.. (2016). Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. Clinical Lymphoma Myeloma & Leukemia. 17(3). 145–151. 9 indexed citations

6.

Heaton, Joanne H., Michelle A. Wood, Alex C. Kim, et al.. (2012). Progression to Adrenocortical Tumorigenesis in Mice and Humans through Insulin-Like Growth Factor 2 and β-Catenin. American Journal Of Pathology. 181(3). 1017–1033. 131 indexed citations

7.

Kim, Alex C., Ferdous M. Barlaskar, Joanne H. Heaton, et al.. (2009). In Search of Adrenocortical Stem and Progenitor Cells. Endocrine Reviews. 30(3). 241–263. 94 indexed citations

8.

Barlaskar, Ferdous M., Aaron C. Spalding, Joanne H. Heaton, et al.. (2008). Preclinical Targeting of the Type I Insulin-Like Growth Factor Receptor in Adrenocortical Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 94(1). 204–212. 140 indexed citations

9.

Barlaskar, Ferdous M. & Gary D. Hammer. (2007). The molecular genetics of adrenocortical carcinoma. Reviews in Endocrine and Metabolic Disorders. 8(4). 343–348. 37 indexed citations

10.

Legakis, Julie E., Jay I. Koepke, Ferdous M. Barlaskar, et al.. (2002). Peroxisome Senescence in Human Fibroblasts. Molecular Biology of the Cell. 13(12). 4243–4255. 143 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact